Contact A Counsellor

counsellor button


teen suicide icon


panic anxiety icon

panic anxiety icon

#MindfulMondays with Miss SA

teen suicide icon


Research on Depression in the Workplace.

For more information please click here



email subscribers list

To subscribe to SADAG's newsletter, click here

To view previous newsletters - click here


Mental Health Matters Journal for Psychiatrists & GP's

MHM Volume 8 Issue1

Click here for more info


journalists crew making newspaper

If you are a journalist writing a story contact Kayla on 011 234 4837  media@anxiety.org.za


MySchool Facebook banner Nov

It’s the small things that make a BIG difference. Sign up for the “My School | My Village | My Planet” Card and start making a difference to Mental Health in South Africa today.

Click Here


cope with cancer book

Literacy is a luxury that many of us take for granted. That is why SADAG created SPEAKING BOOKS and revolutionized the way healthcare information is delivered to low literacy communities.

The customizable 16-page book, read by local celebrity audio recordings, ensures that vital health and social messages can be seen, heard, read and understood by everyone across the world.

We started with books on Teen Suicide prevention , HIV, AIDS and Depression, Understanding Mental Health and have developed over 100+ titles, such as TB, Malaria, Polio, Vaccines for over 45 countries.

suicide speaking book

F.D.A. Strengthens Warnings on Lariam Anti-Malaria Drug

Published: July 29, 2013

The Food and Drug Administration announced on Monday that a commonly used anti-malaria drug must carry the so-called black box warning on its label because of the danger that the drug could cause serious neurological and psychiatric side effects, some of which can become permanent.

The drug, mefloquine hydrochloride — better known by its brand name, Lariam — has long been known to cause side effects that include ringing in the ears, depression and hallucinations. The announcement on Monday clarified that some of the symptoms, like dizziness and loss of balance, could become permanent. And some of the psychiatric symptoms, the agency said, could persist for months or even years after a patient ceases taking the drug. A black box warning is reserved for drugs whose side effects are considered the most severe. The agency warned patients and caregivers to be alert for these side effects and to stop use of the drug if a patient develops neurological or psychiatric symptoms.

Mefloquine was developed by the United States Army, and it entered the commercial market in 1989. Roche, the brand-name manufacturer, no longer sells Lariam in the United States, but generic versions are available.

For years, the drug was favored by travelers not only because of its effectiveness but also because it could be taken once a week, rather than once a day, said Dr. David O. Freedman, director of the travelers’ clinic at the University of Alabama at Birmingham. As warnings on its label steadily increased in severity over the last decade, Dr. Freedman said that his clinic had shifted to other drugs. Ten to 20 percent of his patients traveling to malaria-prone areas now receive a mefloquine prescription, he said.

Mefloquine is the third-most-prescribed anti-malaria drug in the United States, with about 119,000 prescriptions being written for the drug from January of this year through June, according to the research firm IMS Health. Nearly 2.4 million prescriptions were written for the most common anti-malaria drug, hydroxychloroquine, during the same period.

The drug has taken on a dark mythology among many travelers, who have long traded stories about the vivid dreams or strange hallucinations they experienced while taking Lariam. It has also been implicated in cases of violence among military personnel, although others have noted that serious side effects are rare.

The drug’s side effects may play a role in the sentencing trial next month of Staff Sgt. Robert Bales, who pleaded guilty in June to killing 16 Afghan civilians in 2012.
John Henry Browne, Sergeant Bales’s lawyer, said that his client had been given mefloquine on previous deployments, but that he had no confirmation that the soldier was given it on his most recent trip to Afghanistan. Fellow soldiers have testified that Sergeant Bales had been drinking that night. And, in June, Sergeant Bales admitted that he illegally used steroids, which may also have affected his behavior.

“The new F.D.A. report raises new questions of long-term and permanent side effects,” Mr. Browne said in an e-mail message Monday. “This is a fast-developing issue.”


Our Sponsors

Our Partners